For women with primary progressive MS, could bestselling drug be doing more harm than good?

MedicalXpress | avr. 15, 2026

The US Food and Drug Administration (FDA) is reviewing a petition to revoke the approval of Roche's top-selling drug ocrelizumab (Ocrevus) for treating primary progressive multiple sclerosis (PPMS)—a form of MS thought to affect around 15% of patients. The petition alleges that the drug was approved despite internal concerns about a lack of effectiveness in women and a potential increased risk of breast cancer.